Adamas Pharmaceuticals Inc.
| NASDAQ: ADMS | Healthcare / Drugs - Generic / USA |
| 6.65 | +0.1600 | +2.47% | Vol 591 203 | 1Y Perf -30.22% |
| Dec 13th, 2019 16:00 |
| BID | 5.98 | ASK | 6.66 | ||
| Open | 6.47 | Previous Close | 6.49 | ||
| Pre-Market | - | After-Market | 6.66 | ||
| - -% | 0.01 0.15% |
| Target Price | 12.43 | Analyst Rating | Moderate Buy 2.30 | |
| Potential % | 86.92 | Finscreener Ranking | ★★★+ — - | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★+ 46.10 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Market Cap (M) | 185 | Earnings Rating | Strong Sell | |
| Price Range Ratio 52W % | 35.79 | Earnings Date | 7th Nov 2019 |
Today's Price Range 6.386.70 | 52W Range 3.3512.57 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 2.78% | ||
| 1 Month | 18.75% | ||
| 3 Months | 5.06% | ||
| 6 Months | 46.48% | ||
| 1 Year | -30.22% | ||
| 3 Years | -57.04% | ||
| 5 Years | -52.40% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Return on Equity (5Y Avg) | -60.38 | |||
ROE last 12 Months | -165.47 | |||
Return on Assets (5Y Avg) | -29.52 | |||
ROA last 12 Months | -50.73 | |||
Return on Capital (5Y Avg) | -36.89 | |||
ROC last 12 Months | -50.81 | |||
Return on invested Capital Q | -14.73 | |||
Return on invested Capital Y | -60.63 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 6.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
PE Ratio | - | |||
PB Ratio | 9.13 | |||
PS Ratio | 3.57 | |||
Price to Cash Flow | 23.20 | |||
Price to Free Cash Flow | -2.10 | |||
Cash Flow Per Share | -3.12 | |||
Price to Tangible Book | 9.13 | |||
Book Value per Share | 0.71 | |||
Enterprise Value (K) | 164 563 | |||
| Forward PE | -2.61 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Quick Ratio | 5.90 | |||
Current Ratio | 6.30 | |||
Long Term Debt to Total Capital | 0.87 | |||
Total Debt to Equity | 6.80 | |||
Interest Coverage | -6.30 | |||
| Leverage Ratio | 3.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Gross Margin | 95.20 | |||
EBIT Margin | -185.70 | |||
EBITDA Margin | -183.10 | |||
Pre-tax Profit Margin | -5 965.50 | |||
Profit Margin | - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Revenue LTM (K) | 51 604 | |||
Revenue per Share | 1.85 | |||
Revenue Growth 3 Years | 348.39 | |||
Revenue Growth 5 Years | 4.18 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
Dividend Yield | - | |||
Dividend Rate | - | |||
Dividend Growth 3 Years | - | |||
Dividend Growth 5 Years | - | |||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2019 | -0.90 | -0.99 | -10.00 |
| Q02 2019 | -0.98 | -0.90 | 8.16 |
| Q01 2019 | -1.13 | -1.08 | 4.42 |
| Q04 2018 | -1.36 | -1.06 | 22.06 |
| Q03 2018 | -1.34 | -1.22 | 8.96 |
| Q02 2018 | -1.41 | -1.26 | 10.64 |
| Q01 2018 | -1.38 | -1.35 | 2.17 |
| Q04 2017 | -1.15 | -1.27 | -10.43 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2019 QR | -0.95 | -13.10 | Negative |
| 12/2019 FY | -3.91 | -4.55 | Negative |
| 3/2020 QR | -0.82 | -5.13 | Negative |
| 12/2020 FY | -2.47 | -3.35 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -0.90 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 591 203 |
| Shares Outstanding (K) | 27 858 |
| Trades Count | 3 897 |
| Dollar Volume | 4 042 149 |
| Avg. Volume | 483 262 |
| Avg. Weekly Volume | 418 282 |
| Avg. Monthly Volume | 413 981 |
| Avg. Quarterly Volume | 576 427 |
Adamas Pharmaceuticals Inc.
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
CEO: Gregory T. Went
Teplephone: +1 510 450-3500
Address: 1900 Powell Street, Emeryville 94608, CA, USA
